Canada markets open in 1 hour 52 minutes
  • S&P/TSX

    20,954.99
    -218.46 (-1.03%)
     
  • S&P 500

    4,551.68
    -23.11 (-0.51%)
     
  • DOW

    35,490.69
    -266.19 (-0.74%)
     
  • CAD/USD

    0.8092
    +0.0002 (+0.02%)
     
  • CRUDE OIL

    81.32
    -1.34 (-1.62%)
     
  • BTC-CAD

    75,315.40
    +2,198.02 (+3.01%)
     
  • CMC Crypto 200

    1,467.42
    -6.91 (-0.47%)
     
  • GOLD FUTURES

    1,802.00
    +3.20 (+0.18%)
     
  • RUSSELL 2000

    2,252.49
    -43.58 (-1.90%)
     
  • 10-Yr Bond

    1.5290
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,676.75
    +89.50 (+0.57%)
     
  • VOLATILITY

    16.58
    +0.60 (+3.75%)
     
  • FTSE

    7,237.87
    -15.40 (-0.21%)
     
  • NIKKEI 225

    28,820.09
    -278.15 (-0.96%)
     
  • CAD/EUR

    0.6966
    -0.0003 (-0.04%)
     

InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, will report financial results for the fiscal year ended June 30, 2021, on Friday, September 24, 2021.

Conference Call & Webcast*:
Friday, September 24, 2021, at 8:00 AM Pacific Time, 11:00 AM Eastern Time
US/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745
US/CANADA Participant International Dial-In Number: +1 (914) 987-7959
Conference ID: 9373618
Webcast: https://edge.media-server.com/mmc/p/ny89uo2r
(*Webcast replay available for 90 days)

The Company’s full financial statements and related MD&A for the fiscal year ended June 30, 2021 will be available at www.inmedpharma.com, www.sedar.com and at www.sec.gov on September 24, 2021.

About InMed: InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”) and is developing IntegraSyn™ to produce pharmaceutical-grade cannabinoids. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.

Investor Contact:
Colin Clancy
Senior Director, Investor Relations
T: +1 604 416 0999
E: cclancy@inmedpharma.com

Edison Group:
Joe Green/Laine Yonker
T: +1.646.653.7030/+1.646.653.7035
E: jgreen@edisongroup.com / lyonker@edisongroup.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: reporting financial results for the fiscal year ended June 30, 2021on September 24, 2021; delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines; developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol; and, leading the way in the clinical development of cannabinol.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting